SARS-CoV-2 Antibody Response by Age Among BNT162b2 vs mRNA-1273 Vaccine Recipients | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine

Educational Objective
To identify the key insights or developments described in this article

Sign in to take quiz and track your certificates

Buy This Activity

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: June 29, 2021.

Published: September 2, 2021. doi:10.1001/jamanetworkopen.2021.24331

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Richards NE et al. JAMA Network Open.

Corresponding Author: Jeffrey M. Wilson, MD, PhD, Division of Allergy and Clinical Immunology, University of Virginia, PO Box 801355, Charlottesville, VA, 22908 (jmw2gc@virginia.edu).

Author Contributions: Dr Wilson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Richards and Keshavarz contributed equally.

Concept and design: Richards, Keshavarz, Platts-Mills, Wilson.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Workman, Nelson, Platts-Mills, Wilson.

Critical revision of the manuscript for important intellectual content: Richards, Keshavarz, Nelson, Platts-Mills.

Statistical analysis: Keshavarz, Wilson.

Obtained funding: Platts-Mills, Wilson.

Administrative, technical, or material support: Richards, Workman, Nelson, Platts-Mills.

Supervision: Richards, Platts-Mills, Wilson.

Conflict of Interest Disclosures: Drs Platts-Mills and Wilson reported receiving assay support from Thermo-Fisher/Phadia outside the submitted work. Dr Wilson reported receiving consultancy fees from Thermo-Fisher/Phadia and funding for this project from the University of Virginia Manning COVID-19 Research Fund during the conduct of this study. Dr Wilson reported receiving ongoing salary support from AAAAI Faculty Development Award. No other disclosures were reported.

Funding/Support: Dr Platts Mills was supported by grant R37-20565 from the National Institutes of Health.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank all of the study participants.

References
1.
Polack  FP , Thomas  SJ , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.   N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577PubMedGoogle ScholarCrossref
2.
Baden  LR , El Sahly  HM , Essink  B ,  et al; COVE Study Group.  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.   N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389PubMedGoogle ScholarCrossref
3.
Keshavarz  B , Wiencek  JR , Workman  LJ ,  et al.  Quantitative measurement of IgG to severe acute respiratory syndrome coronavirus-2 proteins using ImmunoCAP.   Int Arch Allergy Immunol. 2021;182(5):417-424. doi:10.1159/000514203PubMedGoogle ScholarCrossref
4.
Müller  L , Andrée  M , Moskorz  W ,  et al.  Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination.   Clin Infect Dis. 2021;ciab381. doi:10.1093/cid/ciab381PubMedGoogle Scholar
5.
Abu Jabal  K , Ben-Amram  H , Beiruti  K ,  et al.  Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.   Euro Surveill. 2021;26(6):2100096. doi:10.2807/1560-7917.ES.2021.26.6.2100096PubMedGoogle Scholar
6.
Wajnberg  A , Amanat  F , Firpo  A ,  et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.   Science. 2020;370(6521):1227-1230. doi:10.1126/science.abd7728PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close